Lunai Bioworks Inc · Q3 2026 earnings

Briefing

Lunai Bioworks Inc. reported a net loss of $2.57 million for the third quarter of fiscal 2026 while advancing its AI-driven platform and securing additional financing.

The company generated its first service revenue of $20,942 from a research agreement and narrowed its quarterly net loss compared to prior periods through significant reductions in operating expenses. Cash increased to $3.16 million following equity offerings and debt exchanges, though the company continues to face a substantial working capital deficit and going concern uncertainty. Management is focusing resources on AI biomarker discovery, oncology diagnostics, and therapeutic development while pursuing further funding.

• Service revenue of $20,942 recognized for the first time from a single research services contract with Kapoose Creek Bio.
• General and administrative expenses declined 66% year-over-year to $1.42 million, driving a 65% reduction in total operating expenses.
• Net loss of $2.57 million for the quarter included a $1.09 million loss on debt extinguishment and $70,000 gain from fair value adjustment of contingent consideration.
• Cash position strengthened to $3.16 million after ATM offering and private placement proceeds, with total assets reaching $9.86 million.

Headline financials

Revenue & EPS history

Management plans to secure additional equity or debt financing to support commercialization of AI-driven neurology and oncology diagnostics while streamlining operations around biomarker discovery and therapeutic development.